Table 1 Clinical and tumor characteristics of the LUAD cohorts
| Â | TCGA cohort | GEO cohort |
|---|---|---|
No. of patients | 316 | 381 |
Age (median, range) | 64 (33–86) | 69 (38–89) |
Gender | ||
 Female | 163 (51.6%) | 166 (43.6%) |
 Male | 153 (48.4%) | 215 (56.4%) |
Tumor | ||
 T 1–2 | 275 (87.0%) | NA |
 T 3–4 | 41 (13.0%) | NA |
Node | ||
 N 0–1 | 267 (84.5%) | NA |
 N 2–3 | 49 (15.5%) | NA |
Metastasis | ||
 M 0 | 296 (93.7%) | NA |
 M 1 | 20 (6.3%) | NA |
TNM stage | ||
 I | 164 (51.9%) | 246 (64.6%) |
 II | 76 (24.1%) | 65 (17.1%) |
 III | 56 (17.7%) | 56 (14.7%) |
 IV | 20 (6.3%) | 14 (3.6%) |
TP53 | ||
 Wide type | NA | 287 (75.3%) |
 Mutant type | NA | 94 (24.7%) |
Survival status | ||
 OS years (median) | 2.19 | 2.24 |